Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-06

Clinical Trial Update: A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of LCI699 in essential hypertension has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LCI699 (LCI699)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Essential Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2021-07-06